Basal cell carcinoma (BCC) is the most common human malignancy. Recent advances in our understanding of the critical biologic pathways implicated in the development and progression of BCC have led to the development of the first molecular targeted therapy for this disease. The hedgehog pathway is mutated in virtually all patients with BCC and recent trials with vismodegib, an inhibitor of this pathway, have shown significant responses. This review will discuss the importance of the hedgehog pathway in the pathogenesis of BCC and describe in detail the pharmacology of vismodegib in relation to its activity in advanced BCC.

Original languageEnglish (US)
Pages (from-to)197-203
Number of pages7
JournalCancer Management and Research
Issue number1
StatePublished - Aug 8 2013



  • Basal cell carcinoma
  • Hedgehog pathway
  • Vismodegib

ASJC Scopus subject areas

  • Oncology

Cite this